Patents Assigned to Replimune Limited
  • ALTERED VIRUS
    Publication number: 20240358781
    Abstract: The present invention relates to an oncolytic virus encoding a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody, or an antigen binding fragment thereof.
    Type: Application
    Filed: July 10, 2024
    Publication date: October 31, 2024
    Applicant: Replimune Limited
    Inventor: Robert Stuart Coffin
  • ONCOLYTIC VIRUS STRAIN
    Publication number: 20240301365
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Application
    Filed: May 21, 2024
    Publication date: September 12, 2024
    Applicant: Replimune Limited
    Inventor: Robert Stuart Coffin
  • Altered virus
    Patent number: 12059444
    Abstract: The present invention relates to an oncolytic virus encoding a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody, or an antigen binding fragment thereof.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: August 13, 2024
    Assignee: Replimune Limited
    Inventor: Robert Stuart Coffin
  • Engineered virus
    Patent number: 12049647
    Abstract: The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: July 30, 2024
    Assignee: Replimune Limited
    Inventor: Robert Stuart Coffin
  • Oncolytic virus strain
    Patent number: 12024724
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: July 2, 2024
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Oncolytic virus strain
    Patent number: 11473063
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: October 18, 2022
    Assignee: REPLIMUNE LIMITED
    Inventor: Robert S. Coffin
  • Modified oncolytic virus
    Patent number: 11427810
    Abstract: The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: August 30, 2022
    Assignee: Replimune Limited
    Inventor: Robert S. Coffin
  • Engineered virus
    Patent number: 10947513
    Abstract: The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 16, 2021
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Use of an oncolytic virus for the treatment of cancer
    Patent number: 10626377
    Abstract: The present invention provides a method of treating cancer, which comprises administering a therapeutically effective amount of an oncolytic virus, an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway and a further antagonist of an immune co-inhibitory pathway or an agonist of an immune co-stimulatory pathway to a patient in need thereof.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: April 21, 2020
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Modified oncolytic virus
    Patent number: 10612005
    Abstract: The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: April 7, 2020
    Assignee: REPLIMUNE LIMITED
    Inventor: Robert Coffin
  • Oncolytic virus strain
    Patent number: 10570377
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Replimune Limited
    Inventor: Robert Coffin